Dishman Carbogen Amcis
DCAL · Pharma > Pharmaceuticals & Drugs · Chairman: Janmejay R Vyas · MD: Arpit J Vyas · Listing date: Sept. 22, 2017 · Employees: 929 · Ahmedabad · http://imdcal.com

Stock Price vs Company Growth
1d
1.1%
1w
2.6%
1m
23.8%
3m
13.9%
6m
12.6%
1y
25.6%
5y
12.1%
all
6.4%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 218 1.1%
161
234
Company Overview

Sales
2,619 Cr
Growth: -5.8%
Profit after Tax
-174 Cr
Growth: -29.8%
Small Cap
3,420 Cr
P/S: 1.3x
Industry P/S: 3.1x
Fundamentals

Sales (Cr) ₹ 2,619
Growth -5.8%
EBITDA 10.7%
P/S 1.3x
Dividend 0.0%
P/E -19.7x
Book Value ₹ 2.73
PEG Ratio 3.4x
ROE -11.9%
P/B 79.8x
Shareholding Pattern

Institutions
L And T Mutual Fund Trustee Ltd-L And T Flexicap Fund
2.9 %
Mukul Agrawal
2.55 %
Government Pension Fund Global
2.33 %
Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Flexi Cap Fund
1.88 %
Hbm Healthcare Investment(Cayman) Ltd.
1.62 %
Promoters
Adimans Technologies Llp
59.32 %
Others
Increase    Decrease    No change
Company Profile Detailed

The company is a fully integrated CRAMS player working with global pharmaceutical innovators. It has a global presence with development and manufacturing facilities across Europe, India, and China. It provides end-to-end, integrated, high-value, niche CRAMS offering, right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.
Investors (53)